Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc KNBIF


Primary Symbol: V.KNE

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Post by francoisl13on Sep 11, 2024 9:45am
64 Views
Post# 36218318

Technical analysis

Technical analysisTo see this story with a different angle, let's look at a the technical analysis -- I know, I know it is believed not to be very accurate for micro-cap companies but considering the fact that volume of trades have been picking up this year for KNE why not looking at it ---.
Short Term: Phase 1. Neutral to Negative. The price is below both the EMA 10 and 30. The RSI is below 50. The price range is not very wide so, a news release could change this very quickly considering that the price seems to be holding up well in the $0,12 area.
Mid Term: Phase 3. Neutral to slightly positive. The price sits on the EMA30 but the ema10 is still above the EMA30 so, this is temporary weakness / accumulation level area. The RSI is right at 50.
Long Term: Phase 2. Positive. The price is above the EMA 10. The EMA10 is above the EMA30 whiuch is positive. The volume have picked up well since February of this year. Looks very well long-term.
Voil! It is what it is. Please feel free to comment and add to the above.
GLTA!
<< Previous
Bullboard Posts
Next >>